These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 25669983

  • 1. Drug metabolism and clearance system in tumor cells of patients with multiple myeloma.
    Hassen W, Kassambara A, Reme T, Sahota S, Seckinger A, Vincent L, Cartron G, Moreaux J, Hose D, Klein B.
    Oncotarget; 2015 Mar 20; 6(8):6431-47. PubMed ID: 25669983
    [Abstract] [Full Text] [Related]

  • 2. Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters.
    Clemens J, Seckinger A, Hose D, Theile D, Longo M, Haefeli WE, Burhenne J, Weiss J.
    Cancer Chemother Pharmacol; 2015 Feb 20; 75(2):281-91. PubMed ID: 25477008
    [Abstract] [Full Text] [Related]

  • 3. Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients.
    Macauda A, Castelli E, Buda G, Pelosini M, Butrym A, Watek M, Kruszewski M, Vangsted AJ, Rymko M, Jamroziak K, Abildgaard N, Haastrup EK, Mazur G, Ríos R, Jurczyszyn A, Zawirska D, Dudziński M, Raźny M, Dutka M, Tomczak W, Suska A, Druzd-Sitek A, Marques H, Petrini M, Markiewicz M, Martinez-Lopez J, Ebbesen LH, Iskierka-Jażdżewska E, Sainz J, Canzian F, Campa D.
    Br J Haematol; 2018 Nov 20; 183(3):375-384. PubMed ID: 30079960
    [Abstract] [Full Text] [Related]

  • 4. The effect of Nrf2 knockout on the constitutive expression of drug metabolizing enzymes and transporters in C57Bl/6 mice livers.
    Anwar-Mohamed A, Degenhardt OS, El Gendy MA, Seubert JM, Kleeberger SR, El-Kadi AO.
    Toxicol In Vitro; 2011 Jun 20; 25(4):785-95. PubMed ID: 21281708
    [Abstract] [Full Text] [Related]

  • 5. [Genetic polymorphisms on drug metabolizing enzymes in relation to anti-cancer drug effectiveness].
    Ozawa S.
    Rinsho Byori; 2003 Feb 20; 51(2):168-73. PubMed ID: 12690635
    [Abstract] [Full Text] [Related]

  • 6. Metabolic signature identifies novel targets for drug resistance in multiple myeloma.
    Maiso P, Huynh D, Moschetta M, Sacco A, Aljawai Y, Mishima Y, Asara JM, Roccaro AM, Kimmelman AC, Ghobrial IM.
    Cancer Res; 2015 May 15; 75(10):2071-82. PubMed ID: 25769724
    [Abstract] [Full Text] [Related]

  • 7. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
    Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P.
    Lancet Oncol; 2010 Nov 15; 11(11):1057-65. PubMed ID: 20864405
    [Abstract] [Full Text] [Related]

  • 8. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.
    Inoue J, Otsuki T, Hirasawa A, Imoto I, Matsuo Y, Shimizu S, Taniwaki M, Inazawa J.
    Am J Pathol; 2004 Jul 15; 165(1):71-81. PubMed ID: 15215163
    [Abstract] [Full Text] [Related]

  • 9. Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMEnSE consortium.
    Martino A, Sainz J, Manuel Reis R, Moreno V, Buda G, Lesueur F, Marques H, García-Sanz R, Ríos R, Stein A, Dumontet C, Gemignani F, Maria Rossi A, Landi S, Jurado M, Petrini M, Jamroziak K, Campa D, Canzian F.
    J Hum Genet; 2013 Mar 15; 58(3):155-9. PubMed ID: 23303387
    [Abstract] [Full Text] [Related]

  • 10. Functional crosstalk of CAR-LXR and ROR-LXR in drug metabolism and lipid metabolism.
    Xiao L, Xie X, Zhai Y.
    Adv Drug Deliv Rev; 2010 Oct 30; 62(13):1316-21. PubMed ID: 20659512
    [Abstract] [Full Text] [Related]

  • 11. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
    Bièche I, Girault I, Urbain E, Tozlu S, Lidereau R.
    Breast Cancer Res; 2004 Oct 30; 6(3):R252-63. PubMed ID: 15084249
    [Abstract] [Full Text] [Related]

  • 12. Immunosuppressors and reversion of multidrug-resistance.
    Aouali N, Eddabra L, Macadré J, Morjani H.
    Crit Rev Oncol Hematol; 2005 Oct 30; 56(1):61-70. PubMed ID: 15978826
    [Abstract] [Full Text] [Related]

  • 13. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J, Zhou Y, Thomas GS, Gu Z, Yang Y, Xu H, Tricot G, Zhan F.
    Clin Cancer Res; 2015 Dec 15; 21(24):5532-42. PubMed ID: 26156395
    [Abstract] [Full Text] [Related]

  • 14. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
    Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM, van Kapel J, Groenewegen A, Charnick S, Zittoun R, Löwenberg B.
    Leukemia; 1996 Nov 15; 10(11):1741-50. PubMed ID: 8892677
    [Abstract] [Full Text] [Related]

  • 15. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.
    Wagner M, Halilbasic E, Marschall HU, Zollner G, Fickert P, Langner C, Zatloukal K, Denk H, Trauner M.
    Hepatology; 2005 Aug 15; 42(2):420-30. PubMed ID: 15986414
    [Abstract] [Full Text] [Related]

  • 16. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes.
    Nakagawa Y, Abe S, Kurata M, Hasegawa M, Yamamoto K, Inoue M, Takemura T, Suzuki K, Kitagawa M.
    Am J Hematol; 2006 Nov 15; 81(11):824-31. PubMed ID: 16929535
    [Abstract] [Full Text] [Related]

  • 17. Pregnane X receptor and human malignancy.
    Koutsounas I, Patsouris E, Theocharis S.
    Histol Histopathol; 2013 Apr 15; 28(4):405-20. PubMed ID: 23413096
    [Abstract] [Full Text] [Related]

  • 18. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.
    Moschetta M, Basile A, Ferrucci A, Frassanito MA, Rao L, Ria R, Solimando AG, Giuliani N, Boccarelli A, Fumarola F, Coluccia M, Rossini B, Ruggieri S, Nico B, Maiorano E, Ribatti D, Roccaro AM, Vacca A.
    Clin Cancer Res; 2013 Aug 15; 19(16):4371-82. PubMed ID: 23804425
    [Abstract] [Full Text] [Related]

  • 19. Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease.
    Hungria VT, Latrilha MC, Rodrigues DG, Bydlowski SP, Chiattone CS, Maranhão RC.
    Cancer Chemother Pharmacol; 2004 Jan 15; 53(1):51-60. PubMed ID: 14574458
    [Abstract] [Full Text] [Related]

  • 20. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
    Zaman S, Shentu S, Yang J, He J, Orlowski RZ, Stellrecht CM, Gandhi V.
    Neoplasia; 2015 Mar 15; 17(3):289-300. PubMed ID: 25810013
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.